Medicenna Therapeutics (OTCMKTS:MDNAF) Issues Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Medicenna Therapeutics (OTCMKTS:MDNAF) issued its quarterly earnings results on Thursday. The company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01), Zacks reports.

Medicenna Therapeutics Stock Up 9.1%

Shares of Medicenna Therapeutics stock traded up $0.05 during trading hours on Friday, hitting $0.61. The company’s stock had a trading volume of 138,337 shares, compared to its average volume of 87,005. Medicenna Therapeutics has a 1-year low of $0.55 and a 1-year high of $1.43. The firm has a market capitalization of $50.60 million, a P/E ratio of -5.06 and a beta of 1.81.

Analysts Set New Price Targets

Separately, Zacks Research raised Medicenna Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Monday, January 19th. One research analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat, the company currently has an average rating of “Strong Buy”.

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp. is a clinical-stage biopharmaceutical company focused on developing next-generation cytokine-based immunotherapies for cancer and central nervous system disorders. The company applies protein-engineering approaches to create engineered cytokine therapeutics designed to enhance anti-tumor activity while reducing systemic toxicity, aiming to broaden the therapeutic window for immunomodulatory agents.

Medicenna’s pipeline includes proprietary candidates such as MDNA55, an engineered interleukin-4 (IL-4) receptor-targeted fusion protein developed for intratumoral treatment of recurrent glioblastoma and other brain tumors, and MDNA11, a long-acting engineered interleukin-2 (IL-2) “superkine” intended to stimulate anti-tumor immune responses in solid tumors with an improved safety profile.